Abstract
Ideal cancer therapeutic agents would combine high antitumor activity with little or no toxicity to normal cellular systems. Unfortunately, most cytotoxic agents that are clinically available at the present time are far from fulfilling this ideal. As outlined in the previous chapters, they exert a variable toxicity to the hematopoietic systems and, from a clinical point of view, the granulopoietic system is the most important one. Myelotoxicity is the predominant and therefore the limiting toxicity of a number of chemotherapeutic agents, such as cytosine arabinoside, vinblastine, the alkylating agents and the nitrosoureas; other chemotherapeutic agents (such as MTX, 6-MP, 6-TG, the anthracyclines) may exert limiting toxic effects other than their myelosuppressive action.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1982 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Lohrmann, HP., Schreml, W. (1982). Granulopoietic Toxicity of Cytotoxic Agents: Pathogenesis, Pathophysiology, Methods of Modulation, and Clinical Aspects. In: Cytotoxic Drugs and the Granulopoietic System. Recent Results in Cancer Research, vol 81. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-81690-1_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-81690-1_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-81692-5
Online ISBN: 978-3-642-81690-1
eBook Packages: Springer Book Archive